Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).
David PasquierPhilippe NickersDidier PeiffertPhilippe MaingonPascal PommierThomas LacornerieGeoffrey MartinageEmmanuelle TreschEric LartigauPublished in: PloS one (2017)
ClinicalTrials.gov NCT01596816.